AXSM vs NRXP
AXSM: A biopharmaceutical company developing and commercializing innovative therapies for central nervous system disorders. NRXP: A clinical-stage biopharmaceutical company developing NMDA-modulating neuroplasticity drugs for severe CNS disorders while operating an interventional psychiatric clinic network.
Side-by-side fundamentals
| Metric | AXSM | NRXP | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $159.58 | $2.62 | |
| Market cap | $8.4B | $113M | |
| Net margin FY2025, SEC XBRL | -28.7% | -2336.5% | AXSM higher |
| Operating margin FY2025, SEC XBRL | -26.1% | -1324.4% | AXSM higher |
| ROE FY2025, SEC XBRL | -207.5% | n/a | |
| ROA FY2025, SEC XBRL | -26.6% | -220.9% | AXSM higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 2.26 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +65.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +133.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.66 | 1.07 | |
| 1-year return as of 2026-10-20 close | +21.3% | -20.8% | AXSM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.